Genome-wide association studies (GWAS) involve testing genetic variants across the
genomes of many individuals to identify genotype–phenotype associations. GWAS have …

Many studies have shown that the efficacy and risk of side effects of drug treatment is
influenced by genetic variants. Evidence based guidelines are essential for implementing …

Statins reduce cholesterol, prevent cardiovascular disease, and are among the most
commonly prescribed medications in the world. Statin‐associated musculoskeletal …

Introduction Hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) lower
cholesterol synthesis in patients with hypercholesterolemia. Increased statin exposure is an …

In 2009, the Clinical Pharmacogenetics Implementation Consortium (CPIC, www. cpicpgx.
org), a shared project between Pharmacogenomics Knowledge Base (PharmGKB …

Statins are a cornerstone in the pharmacological prevention of cardiovascular disease.
Although generally well tolerated, a small subset of patients experience statin-related …

This Review is intended to help clinicians, patients, and the public make informed decisions
about statin therapy for the prevention of heart attacks and strokes. It explains how the …

Abstract The Canadian Consensus Working Group has updated its evaluation of the
literature pertaining to statin intolerance and adverse effects. This overview introduces a …

Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch
Pharmacogenetics Working Group provide therapeutic recommendations for well‐known …

Over the past decade, pharmacogenetic testing has emerged in clinical practice to guide
selected cardiovascular therapies. The most common implementation in practice is …